"MAP Kinase Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An abundant 43-kDa mitogen-activated protein kinase kinase subtype with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048369
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.100 D08.811.913.696.620.682.725.200.100 D12.644.360.440.100 D12.776.476.440.100
|
| Concept/Terms |
MAP Kinase Kinase 1- MAP Kinase Kinase 1
- MKK1 Protein Kinase
- MAP2K1 Protein
- Mitogen-Activated Protein Kinase Kinase 1
- Mitogen Activated Protein Kinase Kinase 1
- MKK-1 Protein Kinase
- MKK 1 Protein Kinase
- MEK-1 Protein Kinase
- MEK 1 Protein Kinase
- MAPK Kinase 1
- MEK1 Protein Kinase
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 1".
This graph shows the total number of publications written about "MAP Kinase Kinase 1" by people in this website by year, and whether "MAP Kinase Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 1" by people in Profiles.
-
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022 02 05; 399(10324):541-553.
-
MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harb Perspect Med. 2021 05 03; 11(5).
-
mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK. Cancer Res. 2021 06 15; 81(12):3174-3186.
-
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Cancer Res. 2021 05 15; 81(10):2714-2729.
-
Constitutive activation of mitogen-activated protein kinase kinase (MEK1) in ileal enterocytes leads to dysplasia and a predisposition to cancer. Am J Physiol Gastrointest Liver Physiol. 2021 03 01; 320(3):G366-G379.
-
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clin Cancer Res. 2021 03 15; 27(6):1681-1694.
-
BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice. Blood Adv. 2020 10 13; 4(19):4912-4917.
-
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 11 10; 38(32):3753-3762.
-
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight. 2020 08 06; 5(15).
-
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling. Circ Res. 2020 08 28; 127(6):727-743.